Leiden Jeffrey M's most recent trade in Vertex Pharmaceuticals, Inc. was a trade of 6,066 Common Stock done at an average price of $463.5 . Disclosure was reported to the exchange on Feb. 14, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 463.46 per share. | 14 Feb 2025 | 6,066 | 24,026 (0%) | 0% | 463.5 | 2,811,348 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 7,209 | 32,617 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 450.83 per share. | 12 Feb 2025 | 2,525 | 30,092 (0%) | 0% | 450.8 | 1,138,346 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 15,414 | 25,408 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 499.00 per share. | 30 Aug 2024 | 3,784 | 9,994 (0%) | 0% | 499 | 1,888,216 | Common Stock |
| Vertex Pharma | Jeffrey Leiden M | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 420.58 per share. | 20 Feb 2024 | 4,118 | 13,778 (0%) | 0% | 420.6 | 1,731,948 | Common Stock |
| Vertex Pharma | M Jeffrey Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 419.16 per share. | 14 Feb 2024 | 4,655 | 17,896 (0%) | 0% | 419.2 | 1,951,190 | Common Stock |
| Vertex Pharma | M Jeffrey Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 419.04 per share. | 14 Feb 2024 | 4,356 | 22,551 (0%) | 0% | 419.0 | 1,825,338 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 419.22 per share. | 12 Feb 2024 | 2,009 | 28,291 (0%) | 0% | 419.2 | 842,213 | Common Stock |
| Vertex Pharma | Leiden M Jeffrey | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 419.13 per share. | 12 Feb 2024 | 737 | 26,907 (0%) | 0% | 419.1 | 308,899 | Common Stock |
| Vertex Pharma | Leiden Jeffrey M | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 420.39 per share. | 12 Feb 2024 | 647 | 27,644 (0%) | 0% | 420.4 | 271,992 | Common Stock |
| Vertex Pharma | Leiden M Jeffrey | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 422.74 per share. | 08 Feb 2024 | 8,048 | 30,300 (0%) | 0% | 422.7 | 3,402,212 | Common Stock |
| Vertex Pharma | Leiden M Jeffrey | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 421.73 per share. | 08 Feb 2024 | 2,698 | 38,348 (0%) | 0% | 421.7 | 1,137,828 | Common Stock |
| Vertex Pharma | Jeffrey Leiden M | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 20,452 | 33,339 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | M Jeffrey Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 10,464 | 12,887 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | M Jeffrey Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 7,707 | 41,046 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | M Jeffrey Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 419.07 per share. | 08 Jan 2024 | 6,648 | 2,423 (0%) | 0% | 419.1 | 2,785,977 | Common Stock |
| Vertex Pharma | Leiden Jeffrey M | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 399.41 per share. | 13 Dec 2023 | 13,254 | 9,171 (0%) | 0% | 399.4 | 5,293,780 | Common Stock |
| Vertex Pharma | Leiden M Jeffrey | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 400.19 per share. | 13 Dec 2023 | 100 | 9,071 (0%) | 0% | 400.2 | 40,019 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 349.00 per share. | 05 May 2023 | 1,125 | 35,387 (0%) | 0% | 349 | 392,625 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 349.38 per share. | 05 May 2023 | 708 | 36,683 (0%) | 0% | 349.4 | 247,361 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 350.30 per share. | 05 May 2023 | 171 | 36,512 (0%) | 0% | 350.3 | 59,901 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 349.48 per share. | 02 May 2023 | 4,645 | 43,704 (0%) | 0% | 349.5 | 1,623,335 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 349.22 per share. | 02 May 2023 | 2,008 | 39,891 (0%) | 0% | 349.2 | 701,234 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 350.53 per share. | 02 May 2023 | 1,800 | 38,091 (0%) | 0% | 350.5 | 630,954 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 350.48 per share. | 02 May 2023 | 1,505 | 42,199 (0%) | 0% | 350.5 | 527,472 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 351.59 per share. | 02 May 2023 | 700 | 37,391 (0%) | 0% | 351.6 | 246,113 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 353.18 per share. | 02 May 2023 | 300 | 41,899 (0%) | 0% | 353.2 | 105,954 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.12 per share. | 24 Feb 2023 | 13,730 | 48,349 (0%) | 0% | 289.1 | 3,969,618 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 298.26 per share. | 13 Feb 2023 | 13,344 | 62,079 (0%) | 0% | 298.3 | 3,979,981 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 34,890 | 68,775 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 31,462 | 33,885 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 10,226 | 79,001 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 317.83 per share. | 01 Feb 2023 | 3,578 | 75,423 (0%) | 0% | 317.8 | 1,137,196 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2022 | 60,342 | 33,524 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 91.05 per share. | 25 Jul 2022 | 60,342 | 134,502 (0%) | 0% | 91.0 | 5,494,139 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 282.43 per share. | 25 Jul 2022 | 40,666 | 12,894 (0%) | 0% | 282.4 | 11,485,298 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 281.27 per share. | 25 Jul 2022 | 34,090 | 53,560 (0%) | 0% | 281.3 | 9,588,494 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 280.37 per share. | 25 Jul 2022 | 32,983 | 87,650 (0%) | 0% | 280.4 | 9,247,444 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 279.44 per share. | 25 Jul 2022 | 13,869 | 120,633 (0%) | 0% | 279.4 | 3,875,553 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 283.42 per share. | 25 Jul 2022 | 10,471 | 2,423 (0%) | 0% | 283.4 | 2,967,691 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 289.04 per share. | 13 Apr 2022 | 15,789 | 74,160 (0%) | 0% | 289.0 | 4,563,653 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 227.86 per share. | 24 Feb 2022 | 12,141 | 89,949 (0%) | 0% | 227.9 | 2,766,448 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 232.51 per share. | 17 Feb 2022 | 8,236 | 102,090 (0%) | 0% | 232.5 | 1,914,952 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 28,444 | 78,232 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 20,928 | 99,160 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 17,445 | 116,605 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.63 per share. | 01 Feb 2022 | 6,279 | 110,326 (0%) | 0% | 243.6 | 1,529,753 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 211.75 per share. | 17 Feb 2021 | 13,970 | 49,676 (0%) | 0% | 211.8 | 2,958,148 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 214.16 per share. | 10 Feb 2021 | 13,954 | 63,646 (0%) | 0% | 214.2 | 2,988,389 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 31,498 | 33,809 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 31,462 | 65,271 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 20,928 | 86,199 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 215.03 per share. | 03 Feb 2021 | 8,599 | 77,600 (0%) | 0% | 215.0 | 1,849,043 | Common Stock |